4/7 Psychiatric Genomics Consortium: Advancing Discovery and Impact

4/7 精神病学基因组学联盟：推进发现和影响

基本信息

批准号：
10577733
负责人：
Caroline M Nievergelt
金额：
$ 38.74万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-04-10 至 2026-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10577733
关键词：
Acceleration Address Affect Alleles Biological Biology Biotechnology Cells Clinical Collaborations Communication Communities Country DNA Resequencing Data Diagnostic Disease Educational Materials Ensure Epidemiology Facebook Family Fostering Funding Genes Genetic Genetic Variation Genets Genome Genomics Goals Individual Industry Institution Investments Journals Knowledge Learning Life Maps Measures Medical Medicine Mendelian randomization Mental disorders Meta-Analysis Methods Mission Modeling Molecular National Institute of Mental Health Nature Neurosciences Outcome Paper Patients Phase Phenotype Productivity Psychiatric Diagnosis Psychiatry Recording of previous events Reproducibility Research Personnel Resistance Resources Risk Risk Factors Science Scientist Source Symptoms Therapeutic Time Twitter Update Variant Work base biobank career case control digital media education resources exome exome sequencing experimental study functional genomics genetic architecture genetic pedigree genome sequencing genome wide association study genomic data genomic locus improved innovation insight instrument novel novel therapeutics outreach patient stratification patient subsets predict clinical outcome psychiatric genomics rare variant severe psychiatric disorder statistics success therapeutic development translational potential whole genome working group

项目摘要

Project Summary Now in its 13th year, the Psychiatric Genomics Consortium is perhaps the most innovative and productive experiment in the history of psychiatry. The PGC unified the field and attracted a cadre of outstanding scientists (802 investigators from 157 institutions in 41 countries). PGC work has led to identification of ~500 genetic loci in the 11 psychiatric disorders we study. Our work has led to 320 papers, many in high-profile journals (Nature 3, Cell 5, Science 2, Nat Genet 27, Nat Neurosci 9, Mol Psych 37, Biol Psych 25). As summary statistics are freely available, psychiatric disorders often feature prominently in papers by non-PGC investigators. To advance discovery and impact, we propose to continue the work of the PGC across 11 disorder groups. Considerable new data are coming in the next five years. We thus can rapidly and efficiently increase our knowledge of the fundamental basis of major psychiatric disorders. Aim 1: we will continue to advance genetic discovery for severe psychiatric disorders in all working groups, systematically interface with large biobank studies to ensure maximal comparability, and aggressively promote new studies of individuals with psychiatric disorders from diverse ancestries to increase discovery and improve fine-mapping. Aim 2: most studies analyze common variation (Aim 1), rare CNV (Aim 2), and rare exome/genome resequencing results (via collaboration) in isolation: we will apply an integrative framework to rigorously evaluate the contributions of all measured types of genetic variation on risk for psychiatric disorders. Aim 3: we will move beyond classical case-control definitions to a more biologically-based and nuanced understanding by enabling large trans-diagnostic studies, convene trans-disciplinary teams to use genetics to address unresolved questions about the nature of psychiatric disorders, and to promote large studies of the severest cases seen in psychiatric practice (leveraging the global reach of PGC investigators). Aim 4: we will work to maximize the impact of our work via translational efforts: close collaborations with neuroscience consortia to understand the biological implications of our findings; work to identify modifiable causal risk factors; and work to robustly predict clinical outcomes and identify patient subsets. Aim 5: we will increase impact of our work by extending and formalizing outreach to different communities (including pharma and biotech), via digital media (Twitter, Facebook, Wikipedia), and by developing, distributing, and updating resources/educational material for patients, families, and medical professionals. We will convene a Scientific Advisory Board to ensure we respond positively to those invested in our results Successful completion of this body of work will greatly advance knowledge of the genetic basis of psychiatric disorders with potentially major nosological and treatment implications. These goals are consistent with a core mission of the NIMH, and the central idea of the PGC: to convert the family history risk factor into biologically, clinically, and therapeutically meaningful insights.

项目概要精神病学基因组学联盟如今已进入第 13 个年头，也许是最具创新性和生产力的联盟精神病学史上的实验。 PGC统一了领域并吸引了一批优秀的骨干人员科学家（来自 41 个国家 157 个机构的 802 名研究人员）。 PGC 工作已鉴定出约 500 我们研究的 11 种精神疾病的遗传位点。我们的工作已发表 320 篇论文，其中许多是备受瞩目的论文期刊（Nature 3、Cell 5、Science 2、Nat Genet 27、Nat Neurosci 9、Mol Psych 37、Biol Psych 25）。作为摘要统计数据可免费获取，精神疾病通常在非 PGC 的论文中占据显着位置调查人员。为了推进发现和影响，我们建议继续开展 PGC 的工作，涵盖 11 个领域紊乱群体。未来五年将会出现大量新数据。因此我们可以快速有效地增加我们对主要精神疾病的基本原理的了解。目标 1：我们将继续在所有工作组中推进严重精神疾病的基因发现，系统地与大型生物库研究对接，以确保最大的可比性，并积极促进对来自不同血统的精神疾病个体进行的新研究，以增加发现并改善精细映射。目标 2：大多数研究分析常见变异（目标 1）、罕见 CNV（目标 2）和罕见变异单独的外显子组/基因组重测序结果（通过合作）：我们将应用一个综合框架严格评估所有测量类型的遗传变异对精神疾病风险的贡献。目标 3：我们将超越经典的病例对照定义，转向更加基于生物学和细致入微的定义通过开展大型跨诊断研究来理解，召集跨学科团队利用遗传学来解决有关精神疾病本质的未解决问题，并促进对精神疾病的大规模研究精神病学实践中发现的最严重的病例（利用 PGC 研究人员的全球影响力）。目标4：我们将努力通过转化努力最大限度地发挥我们工作的影响：与神经科学的密切合作联盟来了解我们的研究结果的生物学意义；努力识别可改变的因果风险因素；并致力于稳健地预测临床结果并识别患者子集。目标5：我们将增加通过扩大和正规化对不同社区（包括制药和生物技术），通过数字媒体（Twitter、Facebook、维基百科）以及开发、分发和更新为患者、家庭和医疗专业人员提供的资源/教育材料。我们将召开科学顾问委员会确保我们对那些投资于我们成果的人做出积极回应成功完成这项工作将极大地增进对精神病学遗传基础的了解具有潜在重大疾病分类学和治疗影响的疾病。这些目标与核心一致 NIMH 的使命和 PGC 的中心思想：将家族史危险因素转化为生物学、具有临床和治疗意义的见解。